Podcast ShowPodcasten

The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

385 episodes•0 subscribers•0 Total Listens

Episode Playlist

50 episodes

Nov 21, 2024•—

332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

Dec 5, 2024•—

333: An H5N1 bird flu update and talent scarcity in the radiopharma field

Dec 12, 2024•—

334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children

Dec 19, 2024•—

335: A deep dive on Makary, Vertex's pain data, & 2025 predictions

Jan 9, 2025•—

336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study

Jan 15, 2025•—

337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss

Jan 23, 2025•—

338: Chinese biotechs, a WHO departure, and post-JPM thoughts

Jan 30, 2025•—

339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad

Feb 6, 2025•—

340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug

Feb 13, 2025•—

341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers

Feb 20, 2025•—

342: FDA cuts, zombie biotechs, and too much weight loss?

Feb 27, 2025•—

343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs

Mar 6, 2025•—

344: Trump's FDA commissioner nominee takes the hot seat

Mar 13, 2025•—

345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies

Mar 20, 2025•—

346: Zealand's obesity strategy and Immunovant's curious development plan

Mar 27, 2025•—

347: More HHS upheaval, 23andMe's bankruptcy, and AI for cancer survival

Apr 3, 2025•—

348: Cuts, ousters and drama at the FDA

Apr 10, 2025•—

349: BIO's John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding

Apr 24, 2025•—

350: Pharma tariffs, and a 'sunshine day' for biotech stocks

May 1, 2025•—

351: It's gonna be May (in biotech)

May 8, 2025•—

352: A firebrand takes oversight of vaccines, gene therapies

May 15, 2025•—

353: Trump's drug-pricing plan and a potential Theranos 2.0

May 22, 2025•—

354: Uncertainty in CRISPR world and the start of more M&A

May 29, 2025•—

355: Moderna’s vaccine hit, the MAHA report, and an ASCO preview

Jun 5, 2025•—

356: An AI experiment at the FDA & Novo trailing in the obesity drug race

Jun 12, 2025•—

357: The upheaval of CDC's vaccine panel, and drug pricing confusion

Jun 19, 2025•—

358: FDA's gene therapy turmoil, and an alternative model for funding research

Jun 26, 2025•—

359: Vaccine policy frays, CDC nominee in the hot seat, & obesity drug side effects

Jul 10, 2025•—

360: NIH grant cuts, FDA transparency questions and biotech M&A

Jul 17, 2025•—

361: Inside an FDA drug rejection, and layoffs at Sarepta

Jul 24, 2025•—

362: A mother’s perspective on Sarepta’s gene therapy halt

Jul 31, 2025•—

363: What Vinay Prasad’s ouster means for biotech and the FDA

Aug 7, 2025•—

364: Closing a zombie biotech, and Lilly's disappointing obesity readout

Aug 14, 2025•—

365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended

Aug 21, 2025•—

366: Viking’s obesity flop, ‘pharma to table’ drug sales

Aug 28, 2025•—

367: The ouster of CDC's director, biotech venture firm rankings

Sep 4, 2025•—

368: New stakes in the vaccine dispute and a boost for biotech

Sep 11, 2025•—

369: Trump, Chinese biotech, and an industry career reshaped by illness

Sep 18, 2025•—

370: Pharma sours on the U.K., plus biotech M&A's quiet roll

Sep 25, 2025•—

371: A gene therapy success in Huntington's and Trump's autism announcement

Oct 2, 2025•—

372: A pharma C-suite shakeup and Trump's deal with Pfizer

Oct 9, 2025•—

373: Party in biotech land and AstraZeneca’s miscalculation

Oct 16, 2025•—

374: Veteran biotech executive Clive Meanwell on drug pricing and the obesity market

Oct 23, 2025•—

375: Startups push the FDA and biotech booms in North Carolina

Oct 30, 2025•—

376: BridgeBio’s great week and Moderna’s unraveling

Nov 6, 2025•—

377: Melodrama at the FDA and the Pfizer-Novo bidding war

Nov 13, 2025•—

378: Merck's heart disease win and the FDA's new drug regulator

Nov 20, 2025•—

379: How Mark Cuban plans to ‘f— up’ health care

Dec 4, 2025•—

380: A new top drug regulator and the future of psychedelics

Dec 11, 2025•—

The Readout Loud

Episode Playlist

You May Also Like